OCEAN(a)-DOSE -TIMI 67

A study to evaluate the efficacy, safety, and tolerability of Olpasiran (AMG890, a small interfering RNA) in subjects with elevated lipoprotein(a).

MAIN RESULTS:
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease

N Engl J Med  2022 Nov 17;387(20):1855-1864.

PRESENTATIONS

Reduction of Lipoprotein(a) With Small Interfering RNA – Results of the OCEAN(a)-DOSE (TIMI 67) Trial (O’Donoghue, AHA 2022)
Association of Baseline Lipoprotein(a) and Percentage of Lipoprotein(a) Lowering with Olpasiran (O’Donoghue, ACC 2023)

OTHER PUBLICATIONS

Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction-DOSE Finding Study) Trial. Am Heart J. 2022 May 16;251:61-69.

OCEAN(a)-DOSE on ClinicalTrials.gov

Contact Us about OCEAN(a)-DOSE